DANBURY, Conn., Dec. 11 /PRNewswire-FirstCall/ -- Biodel Inc. today reported fourth quarter and fiscal year ended September 30, 2007 financial results, updated pipeline progress and disclosed 2008 objectives.
“In 2007, our first year as a public company, we advanced our pipeline and achieved critical corporate objectives,” stated Dr. Solomon Steiner, CEO and Chairman of Biodel. “The significant milestones reached include our successful initial public offering, the issuance of Patent No. 7,279,457 encompassing VIAject(TM) and VIAtab(TM), the expansion of the pivotal VIAject(TM) trials into Europe and Asia, and the presentation of additional positive clinical data from our VIAject(TM) program. We look forward to completing the Phase III VIAject(TM) clinical trials and expect to file a New Drug Application for VIAject(TM) by calendar year end 2008.”
Fourth Quarter and Full Year Financial Results
Biodel reported a net loss for the fourth quarter ended September 30, 2007 of $8.4 million, or $0.42 per share, as compared to a net loss of $3.9 million, or $0.36 per share, for the comparable period in the prior year. The fourth quarter 2007 net loss includes $0.6 million of non-cash stock-based compensation expenses.
Net loss applicable to common stockholders for the year ended September 30, 2007 was $27.0 million, or $1.76 per share, as compared to $8.7 million, or $1.05 per share for the year ended September 30, 2006. The net loss includes non-cash charges of $4.2 million, or $0.21 per share, of stock-based compensation and $4.5 million, or $0.22 per share from a deemed dividend charge related to the exercise of warrants at a discounted exercise price.
Biodel reported no revenue during the three months and years ended September 30, 2007 and September 30, 2006.
Research and development expenses were $7.1 million for the three months ended September 30, 2007, compared to $2.3 million for the same period in the prior year. For the 2007 fiscal year, research and development expenses were $15.9 million, compared to $6.0 million for 2006. Both the increase in quarterly and annual expenses were primarily due to costs related to Biodel’s two continuing pivotal Phase III clinical trials for VIAject(TM) and personnel-related expenses. To support the research and development projects and clinical trials, Biodel increased the research and development and clinical staff from eight, in fiscal year 2006, to eighteen. Currently, there are twenty-four research and development and clinical staff.
General and administrative expenses totaled $2.3 million for the three months ended September 30, 2007, compared to $0.6 million for the same period in the prior year. General and administrative expenses totaled $8.4 million for the year ended September 30, 2007, compared to $1.5 million for the comparable period in the prior year. The increase for both the quarter and full year expenses was primarily attributable to $1.0 million and $5.9 million, respectively, in personnel-related expense, including non-cash stock- based compensation expense and performance-based bonus accruals. The non-cash expense for the fiscal year included a $1.7 million charge for options granted to the Board of Directors in May 2007 that vested immediately. The balance of the increase was due to increases in accounting, legal and consulting fees associated with the preparation to become and operate as a public company.
In fiscal year 2007, Biodel increased its general and administrative personnel from eight to twelve. This was associated with the preparation to become and operate as a publicly traded company and further support research and development and clinical projects. Currently, there are seventeen general and administrative personnel.
At the end of fiscal year 2007, Biodel had cash and cash equivalents of $80.0 million and 20.2 million shares outstanding.
Fiscal Year 2007 Corporate & Clinical Highlights
The Company reported progress in advancing the clinical development of its lead product candidates and success in executing its corporate goals:
Calendar Year 2008 Corporate Goals
The company provided details regarding critical 2008 calendar year objectives:
Conference Call and Webcast Information
Biodel’s senior management will host a conference call on December 11, 2007 beginning at 4:30 p.m., Eastern Standard Time, to discuss these financial results and provide a company update. Live audio of the conference call will be available to investors, members of the news media and the general public by dialing 1-877-718-5104 (United States) or 1-719-325-4779 (international). To access the call by live audio webcast, please log on to the Investor section of the Company’s website at www.biodel.com. An archived version of the audio webcast will be available at Biodel’s website through January 11, 2007.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel’s product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA- approved peptide drugs. The Company’s lead product candidate, VIAject(TM), is a rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being tested in two pivotal Phase III clinical trials. Biodel’s pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin in a Phase I clinical trial and two osteoporosis product candidates in pre-clinical studies. For further information regarding Biodel, please visit the Company’s website at http://www.biodel.com.
Safe Harbor
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other then statements of historical facts, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward- looking statements. The words “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company’s forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from those described or implied in the forward-looking statements, including, but not limited to, our ability to secure FDA approval for our product candidates under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act; our ability to market, commercialize and achieve market acceptance for product candidates developed using our VIAdel(TM) technology; the progress or success of our research, development and clinical programs, the initiation and completion of our clinical trials, the timing of the interim analyses and the timing or success of our product candidates, particularly VIAject(TM) and VIAtab(TM); our ability to secure additional patents for VIAject(TM) and our other product candidates; our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; our estimates of future performance; our ability to enter into collaboration arrangements for the commercialization of our product candidates and the success or failure of those collaborations after consummation, if consummated; the rate and degree of market acceptance and clinical utility of our products; our commercialization, marketing and manufacturing capabilities and strategy; our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional financing; and other factors identified in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2007. The Company disclaims any obligation to update any forward-looking statements as a result of events occurring after the date of this press release.
Contact:
Investors, should contact Clay A. Kramer, ckramer@burnsmc.com, or Media, Carney Noensie, cnoensie@burnsmc.com, both of Burns McClellan, Inc., +1-212-213-0006, for Biodel Inc.
CONTACT: Investors: Clay A. Kramer, ckramer@burnsmc.com, or Media: Carney
Noensie, cnoensie@burnsmc.com, both of Burns McClellan, Inc.,
+1-212-213-0006, for Biodel Inc.
Web site: http://www.biodel.com/
